FDA gives final approval for Lupin's generic Depakote

BALTIMORE Lupin Pharmaceuticals has received final approval for a generic version of Abbott Laboratories’ seizure and convulsion treatment medication Depakote.

The generic, divalproex sodium delayed-release, will be available in tablet form in 125 mg, 250 mg and 500 mg strengths.

According to IMS Health, Depakote had sales of about $803 million for the 12 months that ended March 2008.

Shipment of the drug has already begun.